Amgen (AMGN), UCB Announce Significant Data from Phase 3 BRIDGE Study for Increasing BMD in Men With Osteoporosis
Go back to Amgen (AMGN), UCB Announce Significant Data from Phase 3 BRIDGE Study for Increasing BMD in Men With Osteoporosis| Amgen Inc (NASDAQ: AMGN) | Delayed: 273.54 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $273.54 | 52 Week High | $176.85 | |||
| Open | $273.54 | 52 Week Low | $133.64 | |||
| Day High | $273.54 | P/E | 41.20 | |||
| Day Low | $273.54 | EPS | $6.64 | |||
| Volume | 9,637 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 65.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.26 | 52 Week High | $46.25 | |||
| Open | $65.26 | 52 Week Low | $32.74 | |||
| Day High | $65.26 | P/E | N/A | |||
| Day Low | $65.26 | EPS | $0.00 | |||
| Volume | 6 | |||||
